Table 1

OR (95% CI) for the development of antiadalimumab antibodies (AAA) when comparing groups based on baseline methotrexate (MTX) use

No MTXLow doseIntermediate doseHigh dose
Dose0 mg/week5–10 mg/week12.5–20 mg/week≥22.5 mg/week
Patients (n)704054108
Baseline DAS28, mean (SD)5.4 (1.3)5.2 (1.1)5.5 (1.2)5.0 (1.2)
No MTX0.36 (0.18 to 0.74)0.22 (0.10 to 0.46)0.14 (0.07 to 0.28)
Low dose0.60 (0.25 to 1.44)0.39 (0.17 to 0.88)
Intermediate dose0.65 (0.28 to 1.50)
High dose
  • DAS, disease activity score.